Hygeia Healthcare Holdings Co., Ltd. (6078) AI Stock Analysis

• Market Cap: HK$9.41B
• Dividend Yield: N/A
• Average Volume (3M): 4.97M
• Price to Earnings (P/E): 14.9
• Beta (1Y): 1.63
• Revenue Growth: 7.28%
• EPS Growth: -13.77%
• Country: HK
• Employees: 8,169
• Sector: Healthcare
• Sector Strength: 39
• Industry: Medical - Care Facilities
• EPS (TTM): 0.37
• Shares Outstanding: 618,499,000
• 10 Day Avg. Volume: 3,272,193
• 30 Day Avg. Volume: 4,966,765
• PEG Ratio: -0.81
• Price to Book (P/B): 1.32
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 422.69
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$22.45
• Price Target Upside: 46.54% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 68 Neutral
• Price Target: HK$16.50 ▲(7.70%Upside)

Hygeia Healthcare's strong financial performance, characterized by solid profitability and a healthy balance sheet, is offset by cash flow challenges. Technical indicators suggest potential short-term weakness, and while the valuation is reasonable, the lack of a dividend yield may deter some investors. Addressing cash flow issues and achieving positive technical momentum are key to improving the stock's attractiveness.

Hygeia Healthcare Holdings Co., Ltd. Business Overview & Revenue Model

Company Description

Hygeia Healthcare Holdings Co., Ltd. (6078) is a leading oncology-focused healthcare group in China. The company operates a network of specialty hospitals and clinics dedicated to the diagnosis, treatment, and management of cancer. It offers a comprehensive range of oncology services including radiotherapy, chemotherapy, and surgery, supported by advanced medical technologies and a team of experienced healthcare professionals. Hygeia Healthcare's commitment to high-quality patient care and its strategic focus on the oncology segment distinguish it within the Chinese healthcare market.

How the Company Makes Money

Hygeia Healthcare Holdings Co., Ltd. generates revenue primarily through the provision of healthcare services within its network of specialty hospitals and clinics. The key revenue streams include fees charged for diagnostic services, treatment procedures, and inpatient care. The company benefits from China's growing demand for oncology services, driven by an increasing incidence of cancer and a rising awareness of early diagnosis and treatment. Additionally, Hygeia Healthcare may engage in partnerships with medical technology providers to enhance its service offerings, although specific partnership details are null. The company's focus on cost-effective operations and expanding its hospital network further contributes to its revenue growth.

Hygeia Healthcare Holdings Co., Ltd. Financial Statement Overview

Summary

Hygeia Healthcare shows strong revenue growth and profitability, with a robust gross profit margin. However, challenges exist in cash flow generation, particularly in free cash flow and operating cash flow alignment. The balance sheet is stable with manageable leverage, but increasing debt levels could be a future concern.

Income Statement

Hygeia Healthcare demonstrated strong revenue growth and profitability. The gross profit margin was robust at 29.36% for 2024, showing effective cost management. However, net profit margin decreased slightly to 13.45%, indicating some pressure on bottom-line profitability. Revenue grew by 9.06% from 2023 to 2024, showcasing continued expansion, but the slower growth compared to previous years may warrant monitoring.

Balance Sheet

The company's balance sheet reflects a healthy equity position, with a debt-to-equity ratio of 0.42 in 2024, indicating manageable leverage. Return on equity was solid at 8.99%, though slightly down from the previous year, suggesting efficient use of equity capital. The equity ratio is healthy at 60.88%, highlighting financial stability. However, increasing total debt levels could pose future risks.

Cash Flow

Cash flow analysis reveals challenges with free cash flow generation, as free cash flow was null in 2024. The operating cash flow to net income ratio is unavailable, suggesting a need for better alignment of operating cash flows to net income. The company must focus on enhancing cash flow from operations to support ongoing investments and debt obligations.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.45B	4.08B	3.20B	2.32B	1.40B
Gross Profit	1.31B	1.29B	1.02B	744.66M	471.96M
EBITDA	999.10M	1.11B	868.43M	623.67M	385.36M
Net Income	598.26M	682.93M	476.78M	441.46M	170.09M
Balance Sheet
Total Assets	10.93B	10.73B	7.24B	6.69B	4.70B
Cash, Cash Equivalents and Short-Term Investments	651.59M	768.00M	884.71M	1.10B	2.58B
Total Debt	2.79B	2.72B	1.29B	1.23B	2.48M
Total Liabilities	4.25B	4.48B	2.30B	2.21B	359.93M
Stockholders Equity	6.65B	6.23B	4.93B	4.46B	4.27B
Cash Flow
Free Cash Flow	92.02M	-157.98M	92.26M	-236.84M	-25.77M
Operating Cash Flow	707.13M	782.84M	685.38M	426.25M	296.13M
Investing Cash Flow	-671.09M	-2.86B	-372.06M	-850.85M	-2.48B
Financing Cash Flow	-216.56M	1.78B	-154.21M	754.50M	2.17B

Hygeia Healthcare Holdings Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 15.32
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6078, the sentiment is Neutral. The current price of 15.32 is below the 20-day moving average (MA) of 15.51, above the 50-day MA of 15.15, and below the 200-day MA of 15.71, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 49.99 is Neutral, neither overbought nor oversold. The STOCH value of 79.49 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:6078.

Hygeia Healthcare Holdings Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2373	76 Outperform	HK$6.81B	26.84	26.24%	1.63%	17.69%	5.37%
1951	70 Outperform	HK$8.26B	26.29	2.78%	1.98%	-1.04%	-20.43%
6078	68 Neutral	HK$9.41B	14.86	9.30%	―	7.28%	-13.77%
2273	67 Neutral	HK$8.10B	25.02	13.13%	2.39%	28.02%	19.41%
3689	66 Neutral	HK$601.91M	36.22	1.07%	8.89%	-1.20%	-87.51%
1526	66 Neutral	HK$1.70B	5.28	24.13%	4.21%	-3.85%	-19.28%
Sector *	60 Neutral	HK$15.71B	5.67	-7.43%	4.09%	11.60%	-21.06%

Hygeia Healthcare Holdings Co., Ltd. Corporate Events

Hygeia Healthcare Announces AGM Results and Auditor Change

Hygeia Healthcare Holdings Co., Ltd. announced the results of its Annual General Meeting held on June 27, 2025, where all proposed resolutions were passed by shareholder vote. A significant change was the appointment of Deloitte Touche Tohmatsu as the new auditor, which may impact the company’s financial auditing processes and stakeholder confidence.

The most recent analyst rating on (HK:6078) stock is a Buy with a HK$37.00 price target. To see the full list of analyst forecasts on Hygeia Healthcare Holdings Co., Ltd. stock, see the HK:6078 Stock Forecast page.

Hygeia Healthcare Announces 2025 Annual General Meeting

Hygeia Healthcare Holdings Co., Ltd. has announced its upcoming Annual General Meeting scheduled for June 27, 2025, in Hong Kong. The meeting will address several key resolutions, including the adoption of financial statements, re-election of directors, appointment of auditors, and authorization for the board to manage share allotments. These resolutions are crucial for the company’s governance and strategic direction, potentially impacting its operational and financial management.

The most recent analyst rating on (HK:6078) stock is a Buy with a HK$37.00 price target. To see the full list of analyst forecasts on Hygeia Healthcare Holdings Co., Ltd. stock, see the HK:6078 Stock Forecast page.

Hygeia Healthcare Enters New Procurement Agreement with Handan Renhe Hospital

Hygeia Healthcare Holdings Co., Ltd. has entered into a new 2025 Procurement Framework Agreement with Handan Renhe Hospital, replacing the existing procurement agreements. This agreement allows Gamma Star Tech, a subsidiary of Hygeia, to supply medicine and medical consumables to Handan Renhe Hospital, enhancing operational efficiency and continuing their business relationship. The transactions are classified as continuing connected transactions under Hong Kong’s Listing Rules, requiring reporting and annual review but exempt from independent shareholders’ approval due to the percentage ratios involved.

The most recent analyst rating on (HK:6078) stock is a Buy with a HK$37.00 price target. To see the full list of analyst forecasts on Hygeia Healthcare Holdings Co., Ltd. stock, see the HK:6078 Stock Forecast page.

Hygeia Healthcare Announces Board and Operational Changes

Hygeia Healthcare Holdings Co., Ltd. has announced several changes in its board and operations, including the retirement of Mr. Liu Yanqun from his roles as an independent non-executive director and various committee positions, effective May 29, 2025. Mr. Zhang Guozhong, with over 25 years of experience in healthcare management, has been appointed as the new independent non-executive director. Additionally, the company is proposing a change of auditor and has updated its principal place of business in Hong Kong. These changes are expected to enhance the company’s governance and operational efficiency.

The most recent analyst rating on (HK:6078) stock is a Buy with a HK$37.00 price target. To see the full list of analyst forecasts on Hygeia Healthcare Holdings Co., Ltd. stock, see the HK:6078 Stock Forecast page.

Hygeia Healthcare Announces Board Composition and Roles

Hygeia Healthcare Holdings Co., Ltd. has announced the composition of its board of directors and their respective roles within the company. This announcement details the executive and independent non-executive directors, as well as their participation in various board committees, which is crucial for stakeholders to understand the governance structure and leadership dynamics of the company.

The most recent analyst rating on (HK:6078) stock is a Buy with a HK$37.00 price target. To see the full list of analyst forecasts on Hygeia Healthcare Holdings Co., Ltd. stock, see the HK:6078 Stock Forecast page.